Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Comparison of perioperative outcomes and complications of robot assisted radical...
Journal Information
Vol. 43. Issue 6.
Pages 277-283 (July - August 2019)
Share
Share
Download PDF
More article options
Visits
6
Vol. 43. Issue 6.
Pages 277-283 (July - August 2019)
Original article
Comparison of perioperative outcomes and complications of robot assisted radical cystectomy with extracorporeal vs intracorporeal urinary diversion
Comparación de los resultados perioperatorios de la cistectomía radical asistida por robot con derivación urinaria extracorpórea vs. intracorpórea
Visits
6
A. Carrion
Corresponding author
acarrionpuig@gmail.com

Corresponding author.
, A. Piñero, C. Raventós, F. Lozano, F. Díaz, J. Morote
Departamento de Urología, Hospital Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (2)
Table 1. Pre-operative clinical and pathological characteristics of patients undergoing robot cystectomy with extracorporeal and intracorporeal urinary diversion.
Table 2. Perioperative outcomes and complications of patients undergoing robot-assisted radical cystectomy with extracorporeal and intracorporeal urinary diversion.
Show moreShow less
Abstract
Objectives

To compare perioperative outcomes and complications of robot assisted radical cystectomy (RARC) with extracorporeal (ECUD) vs. intracorporeal urinary diversion (ICUD) for bladder cancer.

Material and methods

Retrospective revision of 43 patients who underwent RARC for bladder cancer between 2015 and 2018 with at least 3 months of follow-up. The analysis included the initial series of RARC performed by one surgeon with extensive experience in open radical cystectomy.

Results

Forty-three patients, 40 men (93%) and 3 women (7%), with a median age of 65 years (44–83) and mean follow-up of 27.7 months (±20.1) underwent RARC. A ECUD was performed in 22 cases (51%), of whom 10 were ileal conduits (45.5%) and 12 neobladders (54.5), and ICUD in 21 cases (49%), of whom 14 were ileal conduits (66.7%) and 7 neobladders (33.3%). Clinical and preoperative characteristics were similar in both groups. The median operative time was 360min (240–540) and length of hospital stay was 12 days (7–73). Thirty-five patients (81%) had postoperative complications, of whom 10 (23%) were major. Operative time, peroperative complications, pathological stage, positive margins, and number of lymph nodes removed did not significantly differ among groups. Patients who underwent ECUD had a higher rate of uretero-ileal strictures than those with ICUD (45.5% vs. 14.3%, p=0.026). Among the neobladders, the ECUD developed a higher rate of urethro-neobladder stricture than the ICUD (33% vs. 0%, p=0.044).

Conclusions

RARC with ICUD achieved peroperative outcomes and complication rates comparable than those with ECUD. The ICUD could reduce the risk of developing uretero-ileal and urethro-neobladder strictures.

Keywords:
Bladder cancer
Intracorporeal urinary diversion
Postoperative complications
Robot assisted radical cystectomy
Urinary diversion
Resumen
Objetivos

Comparar los resultados perioperatorios y las complicaciones de la cistectomía radical asistida por robot (CRAR) con derivación urinaria extracorpórea (DUEC) vs. intracorpórea (DUIC).

Material y métodos

Revisión retrospectiva de 43 pacientes sometidos a CRAR por tumor vesical entre 2015-2018 con seguimiento mínimo de 3 meses. Se analizó la serie inicial de CRAR realizada por un cirujano con amplia experiencia en cistectomía radical abierta.

Resultados

Cuarenta y tres pacientes, 40 hombres (93%) y 3 mujeres (7%), con mediana de edad de 65 años (44-83) y seguimiento medio de 27,7 meses (±20,1) fueron sometidos a CRAR. Se realizó DUEC en 22 casos (51%), 10 conductos ileales (45,5%) y 12 neovejigas (54,5%), y DUIC en 21 (49%), 14 conductos ileales (66,7%) y 7 neovejigas (33,3%). Las características clínicas y preoperatorias fueron comparables entre grupos. La mediana de tiempo operatorio fue 360minutos (240-540) y de estancia hospitalaria 12 días (7-73). Treinta y cinco pacientes (81%) presentaron complicaciones postoperatorias, de las cuales 10 (23%) fueron mayores. No se encontraron diferencias en tiempo operatorio, complicaciones perioperatorias, estadificación patológica, márgenes y número de ganglios extirpados entre DUEC y DUIC. Los pacientes sometidos a DUEC presentaron mayor tasa de estenosis uretero-ileal en comparación con la DUIC (45,5% vs. 14,3%, p=0,026). En las neovejigas la DUEC presentó mayor tasa de estenosis uretroneovesical que la DUIC (33% vs. 0%, p=0,044).

Conclusiones

La CRAR con derivación urinaria intracorpórea ofrece resultados perioperatorios y complicaciones comparables a la extracorpórea. La derivación intracorpórea podría reducir el riesgo de desarrollar estenosis ureteroileal y uretroneovesical.

Palabras clave:
Cáncer de vejiga
Derivación urinaria intracorpórea
Complicaciones postoperatorias: Cistectomía radical asistida por robot
Derivación urinaria

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos